We are live on
!
Find out more
MCM
M28 Capital Management Portfolio holdings
AUM
$53.8M
1-Year Est. Return
28.63%
This Fund
S&P 500
This Quarter
Est. Return
-47.15%
1 Year Est. Return
+28.63%
3 Year Est. Return
+218.52%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$128M
AUM Growth
–
Cap. Flow
+$261M
Cap. Flow
% of AUM
203.62%
Top 10 Holdings %
Top 10 Hldgs %
97.32%
Holding
12
New
12
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invivyd
IVVD
|
+$147M |
| 2 |
BridgeBio Pharma
BBIO
|
+$19.7M |
| 3 |
Wave Life Sciences
WVE
|
+$15.6M |
| 4 |
Curis
CRIS
|
+$15.5M |
| 5 |
TG Therapeutics
TGTX
|
+$13.7M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.47% |
| 2 | Financials | 2.53% |
Similar funds
NCM
WEO
MML
CAM
ETCM
AA
TP
GMEI
M28 Capital Management's Q4 2021 Portfolio in Review
Q4 2021 is the first quarter with a 13F filing on record for M28 Capital Management, which disclosed 12 positions worth $128M. Its ten largest holdings account for 97% of the portfolio.
Its largest position is Invivyd: 5,665,221 shares worth $41.1M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, followed by Financials.
- M28 Capital Management's largest Q4 2021 buy was Invivyd: 5,665,221 shares worth $41.1M.
- M28 Capital Management's ten largest holdings make up 97% of its $128M portfolio in Q4 2021.
- M28 Capital Management disclosed 12 positions in Q4 2021, its first 13F filing on record.
Based on M28 Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.